Author/Editor		Rožman, P; Karas, M; Košir, A; Labar, B; Madrigal, A; Middleton, D; Navarrete, C; Oudshoorn, M; Schemmach, H; Vitek, A; Bohinjec, M
Title		Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?
Type		članek
Source		Bone Marrow Transplant
Vol. and No.		Letnik 31
Publication year		2003
Volume		str. 497-506
Language		eng
Abstract		The role of human platelet alloantigens (HPA) in clinical bone marrow allotransplantation was investigated. The leading hypothesis was that HPA alloepitopes act as minor histocompatibility antigens and aggravate graftversus-host disease (GVHD). To exclude the effect of MHC disparity, only HLA identical donor-recipient pairs were entered into the study. The influence of HPA compatibility on overall survival, occurrence of relapses and haematopoietic recovery was also investigated. A total of 223 patients who received a graft from an HLAidentical sibling, genotyped for HPA -1, -2, -3, -4 and -5, were observed over a post-transplant period of 24 months following the protocol recommended by EBMT. The data from patients having received grafts from HPA compatible donors were compared to data from patients having received grafts that were mismatched in HPA allotypes in the GVH direction. Analysis of the incidence of acute and chronic (GVHD), overall survival, relapse incidence, haematopoietic recovery and some other clinical parameters did not reveal any significant difference between the HPA-matched and -mismatched groups of patients, regardless of their age. Our results give no evidence that HPA-1, -2, -3 and -5 alloantigens should be considered minor transplantation antigens in clinical bone marrow transplantation.
Descriptors		BONE MARROW TRANSPLANTATION ISOANTIGENS BLOOD PLATELETS TRANSPLANTATION, HOMOLOGOUS MINOR HISTOCOMPATIBILITY ANTIGENS GRAFT VS HOST DISEASE GENOTYPE POLYMORPHISM (GENETICS) POLYMERASE CHAIN REACTION HISTOCOMPATIBILITY TESTING PLATELET MEMBRANE GLYCOPROTEINS